Advertisement

Topics

Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 35-page report is available in PDF from $2000.

Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015’, provides an overview of the Premenstrual Dysphoric Disorder (PMDD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premenstrual Dysphoric Disorder (PMDD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premenstrual Dysphoric Disorder (PMDD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premenstrual Dysphoric Disorder (PMDD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Premenstrual Dysphoric Disorder (PMDD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Premenstrual Dysphoric Disorder (PMDD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premenstrual Dysphoric Disorder (PMDD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Premenstrual Dysphoric Disorder (PMDD) Overview 6
Therapeutics Development 7
Pipeline Products for Premenstrual Dysphoric Disorder (PMDD) - Overview 7
Pipeline Products for Premenstrual Dysphoric Disorder (PMDD) - Comparative Analysis 8
Premenstrual Dysphoric Disorder (PMDD) - Therapeutics under Development by Companies 9
Premenstrual Dysphoric Disorder (PMDD) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Premenstrual Dysphoric Disorder (PMDD) - Products under Development by Companies 12
Premenstrual Dysphoric Disorder (PMDD) - Companies Involved in Therapeutics Development 13
Azevan Pharmaceuticals, Inc. 13
Pherin Pharmaceuticals, Inc. 14
Umecrine Mood AB 15
Premenstrual Dysphoric Disorder (PMDD) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 24
PH-80PMD - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule-1 to Antagonize GABAA Receptor for PMDD - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecule-2 to Antagonize GABAA Receptor for PMDD - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SRX-251 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
UC-1010 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Premenstrual Dysphoric Disorder (PMDD) - Recent Pipeline Updates 31
Premenstrual Dysphoric Disorder (PMDD) - Product Development Milestones 32
Featured News & Press Releases 32
Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD) 32
May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

For more information open Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015.

SKU: GMDHC6795IDB

Original Article: Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...